J&J wins FDA accelerated approval for RYBREVANT FASPRO in advanced head and neck cancer
FROM THE WIRE · FINANCE.YAHOO.COM
Accelerated approval based on data demonstrating clinically meaningful efficacy, including a 42 percent overall response rate (95 percent confidence interval, 32–52 percent)1 First advancement in the second-line treatment setting for recurrent or metastatic head and neck cancer…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishRegulatory approval of a new treatment for a mega-cap pharma, relevant but with limited impact on the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The FDA granted accelerated approval for RYBREVANT FASPRO as a single agent.
- 02The overall response rate was 42% in the data presented.
- 03The drug is indicated for adults with recurrent or metastatic head and neck cancer in the second line.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets